Literature DB >> 3279894

Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants.

K Antman1, R P Gale.   

Abstract

The response of human breast cancer to drugs and radiation is dose-dependent, with higher doses producing increased response rates. However, dose escalation of several agents active against breast cancer is limited by bone marrow toxicity. This limitation can be overcome in some instances by transplantation of bone marrow cells. We evaluated 27 trials of bone marrow autotransplants in 172 patients who received single or multiple drug chemotherapy, radiation, or both. The overall response rate was 58%. Response rates were highest in trials involving multiple alkylating agents (76%) or previously untreated patients (81%). These data suggest that high-dose therapy and bone marrow autotransplants can produce remissions in patients with advanced breast cancer unresponsive to conventional therapy. A critical evaluation of this approach will require controlled trials in high-risk persons.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279894     DOI: 10.7326/0003-4819-108-4-570

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

1.  Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer.

Authors:  H Gilbert Welch; Juliana Mogielnicki
Journal:  BMJ       Date:  2002-05-04

Review 2.  Systemic therapy of advanced breast cancer.

Authors:  H T Mouridsen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

3.  Overview of new treatments for breast cancer.

Authors:  G N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Selecting dose-intense drug combinations: metastatic breast cancer.

Authors:  E L Korn; R Simon
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

Review 5.  Bone marrow transplantation. Part II--autologous.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1990-01

Review 6.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

7.  Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.

Authors:  D Faulds; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

8.  New biologies and therapies for breast cancer.

Authors:  B M Cantwell
Journal:  Ir J Med Sci       Date:  1988-07       Impact factor: 1.568

9.  Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF).

Authors:  J A Neidhart
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

Review 10.  Response to treatment of breast cancer.

Authors:  J L Berenberg
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.